Immunoassay Interference Blocker Market

Market Study on Immunoassay Interference Blockers: Increasing Need for Biochemical Testing to Drive Market Growth

Immunoassay Interference Blocker Market Segmented Antibody Interference Blockers, Detection Interference Blockers, Surface Interference Blockers Product in Sandwich Immunoassays, Antibody Capture Assays, Competitive ELISA Application

  • December-2021
  • PMRREP24343
  • 245 Pages
  • Healthcare

Market Snapshot

The global immunoassay interference blocker market is expected to experience a significant growth rate at 6.7% CAGR from 2021 to 2031, with an estimated market value of around US$ 455 Mn by 2031. As per Persistence Market Research’s projections, antibody interference blockers held a substantial share of over 54% in 2020 within the global market.

In 2020, immunoassay interference blocker consumption accounted for nearly 2% of the global molecular diagnostics market.

Immunoassay Interference Blocker Market Size (2020)

US$ 223 Mn

Projected Market Value (2031)

US$ 455 Mn

Global Market Growth Rate (2021-2031)

6.7% CAGR

Market Share of Top 5 Countries


Find Out More about the Report Coverage


  • Abcam plc
  • AMS BioApplication (Europe) Limited
  • Aviva Systems Biology Corporation
  • Bio-Rad Laboratories, Inc.
  • Meridian Bioscience, Inc.
  • Roche Diagnostics GmbH
  • Rockland Immunochemicals, Inc.
  • Scantibodies Laboratory, Inc.
  • Thermo Fisher Scientific

Sales Analysis of Immunoassay Interference Blockers from 2016 to 2020 Vs Market Outlook for 2021 to 2031

Rapidly rising prevalence of chronic diseases and increasing aging population across the world are expected to fuel the need for biochemical testing, and would immunoassay interference blocker demand owing to increased adoption of immunoassay interference blocker kits and reagents.

The immunoassay interference blocker market holds major potential in the near future, due to application across various immunoassay tests and diagnostic assays owing to collaborative R&D among researchers and manufacturers to develop and introduce newer and more efficient immunoassay interference blockers.

Immunoassay interference blockers such antibody interference blockers, detection interference blockers, and surface interference blockers used to perform immunoassays with least interference have gained traction over the last two decades.

Emerging molecular technologies to diagnose infectious diseases at the point or treat diseases such as cancer, all-new technological innovations such as chips and micro arrays, fluorescent in-situ hybridization, antibody capture assays, competitive ELISA, sandwich immunoassay, sequencing, and others are fuelling growth of the market for immunoassay interference blockers.

The global market expanded at 4.6% CAGR over the past 5 years, and is set to progress faster at a CAGR of 6.7% through 2031.

Customize this Report

Explore Intelligence Tailored to Your Business Goals.

What are the Key Opportunities for Immunoassay Interference Blocker Manufacturers?

Presence of a well-structured regulatory framework for biochemical testing in developed regions, specifically North America and Europe, have been playing a prime role in shaping the prospects of the global market for immunoassay interference blockers. Furthermore, increase in the number of biotechnology companies, CROs, and molecular diagnostic companies will also drive the need for immunoassay interference blockers.

Global health issues such as COVID-19, H1N1, Ebola, etc., are also boosting the requirement of different accurate molecular diagnostic techniques, which signifies the growth potential for the market.

Furthermore, academic institutes and research organizations along with biotechnology companies have developed themselves into a protruding consumer base, branded by under-explored product segments for immunoassay interference blockers to realize the high performance quality of immunoassays. This has allowed immunoassay interference blocker manufacturers to benefit from the emerging dormant opportunity.

Suppliers of immunoassay interference blockers are converging to bring in novel technologies, kits, and reagents that can efficiently diagnose various chronic diseases. This is expected to elucidate hostility of progression of cancer and other viral as well as infectious diseases and the expected patient survival period. This presents an opportunistic industry growth whilst maintaining the research continuum in molecular diagnostics.

Market Research Methodology - Perfected through Years of Diligence

A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.

Get actionable insights on Ship Repair And Maintenance Services Market

What’s Restraining for Immunoassay Interference Blocker Demand?

FDA approvals for immunoassay interference blocker kits and reagents are severely deterring the expansion of the global market for immunoassay interference blockers. Molecular diagnostic reagents, including immunoassay interference blocker kits, do not have any clinical results on medical usage. Thus, delay in FDA approvals for immunoassay interference blockers have created potential complications.

The market is also being hindered by lack of reimbursement policies and lack of information and shortage of transparency regarding diagnostic procedures used for detecting different infections and chronic conditions. These are among the primary key challenges hindering growth of the overall market.

Prices of molecular testing are unaffordable for various laboratories outside extremely industrialized Western countries. Apart from this, consumables and hardware investments are the major cost factors restricting the dissemination of molecular diagnosis in clinical diagnostic laboratories.

Thus, the immunoassay interference blocker-based market is being hindered by the unfavourable reimbursement scenario in several regions, as it is restraining the growth of innovative technologies such as human serum-derived antibody interference blockers.


Explore Persistence Market Research’s expertise in promulgation of the business !

Country-wise Insights

What Makes the U.S. the Largest Market for Immunoassay Interference Blockers?

The U.S. market dominated the North American region with a total market share of 92.9% in 2020, and is slated to continue experiencing huge growth throughout the decade.

Growth of this market is driven by increasing molecular diagnosis, rising demand for affordable treatment and cost-effective therapies, established and growing healthcare system, and presence of major suppliers of immunoassay interference blockers in the country.

Why is Germany the Most Lucrative Market for Immunoassay Interference Blockers in Europe?

Germany dominated the European market for immunoassay interference blockers with a share of 21.6% in 2020. Germany possesses considerable institutional funding for research & development, due to which, the quality of research has intensified in the European region.

Furthermore, inorganic growth initiatives adopted by key players to expand the immunoassay interference blocker industry across the European region would speed up regional progress even further.

Category-wise Insights

Why are Antibody Interference Blockers Driving Most Market Growth?

By product, antibody interference blockers project high growth at a CAGR of 6.4% till the end of the forecast period. This high growth is associated with their use in diagnostic assays to reduce non-specific binding and other interference that can possibly lead to false positive results.

Which Immunoassay Interference Blocker Application is Most Widely Adopted?

Antibody capture assays held a revenue share of 39.8% in 2020, which is projected to increase over the decade. High growth is associated with the specificity of capture antibodies to the target antigen.

Impact of COVID-19

With growing disease outbreaks and frequent epidemics, the need for easy-to-use immunoassay interference blocker systems will continue to grow at an increasing pace. Governments across the world are trying their best to deal with the pandemic, which requires aggressive testing to stop the spread of infection.

Rising evidence based on the efficacy of combination of two lateral flow immunoassay tests for the detection of COVID-19 immunoglobulins has enhanced the scope of molecular diagnostics. These tests would meet urgent need of utilization with effective results. The pandemic is thus a driving factor for the sales growth of immunoassay interference blockers.

Competitive Landscape

Leading suppliers of immunoassay blockers are actively involved in strategic expansions by way of collaborations and new product developments to strengthen their market presence.

  • In February 2021, Abingdon Health signed a collaboration and co-marketing agreement with Abcam plc, a global leader in the supply of life science research tools and reagents.
  • In January 2021, Abcam, a global innovator in life science reagents and tools, and Shuwen Biotech (Shuwen), a leading Chinese company focusing on the development and commercialization of companion diagnostics, announced the signing of an extended strategic cooperation agreement. The agreement will enable expanded collaboration on important companion diagnostic targets that have emerged in recent years.

Similarly, recent developments related to companies manufacturing immunoassay interference blocker products have been tracked by the team at Persistence Market Research, which are available in the full report.

Immunoassay Interference Blocker Industry Report Scope



Forecast Period


Historical Data Available for


Market Analysis

US$ Mn for Value

Key Regions Covered

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • The Middle East & Africa

Key Countries Covered

  • U.S.
  • Canada
  • Brazil
  • Mexico
  • Argentina
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • China
  • Japan
  • South Korea
  • India
  • Thailand
  • Indonesia
  • Malaysia
  • Australia
  • New Zealand
  • GCC Countries
  • Turkey
  • South Africa

Key Market Segments Covered

  • Product
  • Application
  • End User
  • Region

Key Companies Profiled

  • Abcam plc
  • AMS Biotechnology (Europe) Limited
  • Aviva Systems Biology Corporation
  • Bio-Rad Laboratories, Inc.
  • Meridian Bioscience, Inc.
  • Roche Diagnostics GmbH
  • Rockland Immunochemicals, Inc.
  • Scantibodies Laboratory, Inc.
  • Thermo Fisher Scientific


Available upon Request

Key Segments Covered in Immunoassay Interference Blocker Industry Research

By Product

  • Antibody Interference Blockers
  • Detection Interference Blockers
  • Surface Interference Blockers

By Application

  • Sandwich Immunoassays
  • Antibody Capture Assays
  • Competitive ELISA
  • Others

By End User

  • Biotechnology Companies
  • Contract Research Organizations
  • Academic and Research Institutes
  • Molecular Diagnostics Companies

- FAQs -

The global market for immunoassay interference blockers was worth US$ 223 Mn in 2020, and is set to expand 1.9X over the next ten years.

The immunoassay interference blocker-based market is expected to reach US$ 455 Mn by the end of 2031, with sales revenue expected to register 6.7% CAGR.

From 2016-2020, the global immunoassay interference blocker industry expanded at 4.6% CAGR.

Well-structured regulatory framework in developed countries, increasing consolidations among key players, technology advancements, and increasing product consolidation activities are some of the key trends being witnessed in this marketplace.

The U.S., Japan, China, Germany, and India are expected to drive most demand for immunoassay interference blocker products.

North America is one of the key markets for immunoassay interference blockers, with the U.S. expected to account 92.9% regional market share.

Demand for immunoassay interference blockers in Europe is expected to register growth at 6.4% CAGR over the next ten years.

The U.S., Japan, and Germany are key producers of immunoassay interference blocker products.

The South Korea market is expected to exhibit a high CAGR of 7.4%, while Japan holds a revenue share of over 50% in the East Asia market for immunoassay interference blockers.


Intravenous Immunoglobulin Market

The global intravenous immunoglobulin market is likely to reach a market value of US$ 12,000 Million in 2022 and is expected to accumulate a market value of US$ 25,884 Million by registering a CAGR of 7.9% in the forecast period 2022-2032. .

Urothelial Carcinoma Diagnostics Market

Global Market Study on Urothelial Carcinoma Diagnostics - Novel Biomarkers' market share, size, valuation, revenue, CAGR, growth demand, outlook, key players & forecast.

Adult Hemoglobinopathy Testing Market

The global adult hemoglobinopathy testing market is projected to grow at a CAGR of 3.9% throughout the forecast period, Favorable reimbursement for adult hemoglobinopathy testing is expected to drive the growth of the adult hemoglobinopathy testing market over the forecast period..

HbA1c Analyzers Market

The hba1c analyzers market has been analyzed in terms of value (us$ MN) and volume (units). The report also offers crucial information on the market structure, to equip the stakeholders of the hba1c analyzers market with an incisive view of the competitive landscape..

Our Clients

Our Clients